Investors seeking to outperform the market often focus on hand-picking stocks. Selecting the right ones has proven to be a key factor in boosting wealth.
As of close of business last night, Cue Biopharma Inc’s stock clocked out at $1.45, down -9.37% from its previous closing price of $1.60. In other words, the price has decreased by -$9.37 from its previous closing price. On the day, 0.17 million shares were traded. CUE stock price reached its highest trading level at $1.6 during the session, while it also had its lowest trading level at $1.41.
Ratios:
To gain a deeper understanding of CUE’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.22 and its Current Ratio is at 2.22. In the meantime, Its Debt-to-Equity ratio is 0.37 whereas as Long-Term Debt/Eq ratio is at 0.10.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on March 13, 2024, initiated with a Buy rating and assigned the stock a target price of $6.
On November 21, 2022, Piper Sandler started tracking the stock assigning a Overweight rating and target price of $7.Piper Sandler initiated its Overweight rating on November 21, 2022, with a $7 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Dec 16 ’24 when PASSERI DANIEL R bought 30,000 shares for $1.03 per share. The transaction valued at 30,900 led to the insider holds 164,578 shares of the business.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CUE now has a Market Capitalization of 91857936 and an Enterprise Value of 41794928. For the stock, the TTM Price-to-Sale (P/S) ratio is 9.64 while its Price-to-Book (P/B) ratio in mrq is 3.44. Its current Enterprise Value per Revenue stands at 5.039 whereas that against EBITDA is -0.876.
Stock Price History:
The Beta on a monthly basis for CUE is 1.61, which has changed by -0.5182724 over the last 52 weeks, in comparison to a change of 0.23806548 over the same period for the S&P500. Over the past 52 weeks, CUE has reached a high of $3.20, while it has fallen to a 52-week low of $0.45. The 50-Day Moving Average of the stock is 13.26%, while the 200-Day Moving Average is calculated to be 18.42%.
Shares Statistics:
It appears that CUE traded 634.28K shares on average per day over the past three months and 491550 shares per day over the past ten days. A total of 63.35M shares are outstanding, with a floating share count of 62.87M. Insiders hold about 0.75% of the company’s shares, while institutions hold 23.54% stake in the company. Shares short for CUE as of 1730332800 were 1780964 with a Short Ratio of 1.70, compared to 1727654400 on 3800384. Therefore, it implies a Short% of Shares Outstanding of 1780964 and a Short% of Float of 2.98.
Earnings Estimates
A comprehensive evaluation of Cue Biopharma Inc (CUE) is underway, with the input of 2.0 analysts contributing to its current rating.The consensus estimate for the next quarter is -$0.15, with high estimates of -$0.13 and low estimates of -$0.17.
Analysts are recommending an EPS of between -$0.74 and -$0.77 for the fiscal current year, implying an average EPS of -$0.75. EPS for the following year is -$0.57, with 2.0 analysts recommending between -$0.54 and -$0.6.
Revenue Estimates
A total of 5 analysts have provided revenue estimates for CUE’s current fiscal year. The highest revenue estimate was $11.21M, while the lowest revenue estimate was $7.71M, resulting in an average revenue estimate of $9.41M. In the same quarter a year ago, actual revenue was $5.49M
